NNC0721-8060: NNC0721-8060 will be administered subcutaneously.
Semaglutide: Semaglutide will be administered subcutaneously.
Placebo: Placebo will be administered subcutaneously.
Study summary
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Male or female (sex at birth).
* Age 18-55 years (both inclusive) at the time of signing informed consent.
* Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
* Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.
Exclusion Criteria:
* Known or suspected hypersensitivity to study intervention(s) or related products.
* Previous randomisation in this study.
* History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
* Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
* Current participation (signed informed consent) in any other interventional clinical study.
* Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
* Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
* Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.
Primary outcome measure(s)
Part A: Number of treatment emergent adverse events (TEAE) — From Day 1 to Day 36 Measured as number of events.
Part B: Number of treatment emergent adverse events (TEAE) — From Day 1 to Day 57 Measured as number of events.
Part C: Change from baseline in body weight — From Day 1 to Day 85 Measured as percentage change in body weight.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.